Anavex Life Sciences Corp (AVXL)

[Lima4918]

The sigma-1 receptor activator Anavex 2–73 has entered a phase III clinical trial after it was granted fast-track status by the FDA because of the promising results in phase II.

The company has not been granted Fast Track anything by the FDA yet, so this news is no oversight and no error on the part of Nature.

This is rip off your head kind of news for shorts.

I wonder what the nature of those conversations Anavex had with shareholders in the past few days..